Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia
نویسندگان
چکیده
منابع مشابه
Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review
INTRODUCTION Hyperkalemia is a serious medical condition that often manifests in patients with chronic kidney disease and heart failure. Renin-angiotensin-aldosterone system inhibitors are known to improve outcomes in these disease states but can also cause drug-induced hyperkalemia. New therapeutic options exist for managing hyperkalemia in these patients which warrant evidence-based evaluatio...
متن کاملSodium zirconium cyclosilicate (ZS-9) treatment in patients with serum potassium >6.5 mEq/L
I am writing in regards to an inaccuracy in the recent case report published in the Journal of Community Hospital Internal Medicine Perspectives by Karmacharya et al. (1). The authors had stated that sodium zirconium cyclosilicate (ZS-9) along with patiromer sorbitex calcium (patiromer) has not been studied in patients with serum potassium (K ) concentrations 6.5 mEq/L. However, it should be no...
متن کاملEffect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial.
IMPORTANCE Hyperkalemia is a common electrolyte abnormality that may be difficult to manage because of a lack of effective therapies. Sodium zirconium cyclosilicate is a nonabsorbed cation exchanger that selectively binds potassium in the intestine. OBJECTIVE To evaluate the efficacy and safety of zirconium cyclosilicate for 28 days in patients with hyperkalemia. DESIGN, SETTING, AND PARTIC...
متن کاملMaintenance of serum potassium with sodium zirconium cyclosilicate (ZS‐9) in heart failure patients: results from a phase 3 randomized, double‐blind, placebo‐controlled trial
AIMS Hyperkalaemia in heart failure patients limits use of cardioprotective renin-angiotensin-aldosterone system inhibitors (RAASi). Sodium zirconium cyclosilicate (ZS-9) is a selective potassium ion trap, whose mechanism of action may allow for potassium binding in the upper gastrointestinal tract as early as the duodenum following oral administration. ZS-9 previously demonstrated the ability ...
متن کاملHyperkalaemia.
Hyperkalaemia is defined as serum potassium concentration greater than 5.5 mmol/l. Its prevalence in the general population is unknown, but it is thought to occur in 1-10% of patients admitted to hospital.1 The rate of morbidity and mortality associated with hyperkalaemia has risen greatly with the use of drugs that target the renin-angiotensin system, and since publication 10 years ago of a ra...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drugs
سال: 2018
ISSN: 0012-6667,1179-1950
DOI: 10.1007/s40265-018-0991-6